PharmaLegacy Labs, a Shanghai preclinical CRO, has formed a strategic alliance with Normalline of Beijing. Normalline offers regulatory guidance for medical device companies seeking entry to China’s market. The two companies positioned the alliance as a combination of Normalline’s regulatory device expertise, which has a 100% approval success rate since its founding in 2008, with PharmaLegacy’s animal models and bone/orthopedics capabilities.
